ArticleDiscover oncology2025
Diagnostic and management strategies for retroperitoneal leiomyosarcoma invading the inferior vena cava: a case report.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Giant retroperitoneal leiomyosarcoma of massive proportions: a case report.International journal of surgery case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetroperitoneal leiomyosarcoma represents a poor-prognosis malignancy for which current clinical treatment options remain limited. This study may further help bridge the gap in available therapeutic modalities. CASE PRESENTATION: This case report describes a 75-year-old female patient who was admitted to the hospital with right lower abdominal pain and imaging studies suggesting a retroperitoneal mass and consideration of leiomyosarcoma. After the diagnosis was confirmed by imaging analysis combined with puncture biopsy, the patient received chemotherapy with adriamycin (75 mg/m²) and dacarbazine (200 mg/m²) to shrink the tumor once every 3 weeks for 4 cycles, which resulted in tumor shrinkage, and then underwent resection of the retroperitoneal leiomyosarcoma combined with resection of the inferior vena cava lesions. The retroperitoneal tumor involving the inferior vena cava (IVC) was completely resected without requiring IVC reconstruction during the surgical procedure. Final histopathological analysis confirmed the diagnosis of leiomyosarcoma. The patient demonstrated an uneventful postoperative recovery with no surgical complications, and subsequent follow-up evaluations revealed no evidence of disease recurrence, resulting in substantial improvement in the patient's quality of life on the basis of standardized oncology performance metrics.
conclusionsThis case emphasizes the critical role of imaging in diagnosis and surgical strategies. This study provides new ideas for the complete resection of retroperitoneal leiomyosarcoma. More studies are needed in the future to optimize the treatment strategy for this type of tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.